Both interleukin-8 receptors independently mediate chemotaxis Jurkat cells transfected with IL-8R1 or IL-8R2 migrate in response to IL-8, GROα and NAP-2 by Loetscher, Pius et al.
FEBS Letters 341 (1994) 187-192 LETTERS 
ELSEVIER 
FEBS 13809 
Both interleukin-8 receptors independently mediate chemotaxis 
Jurkat cells transfected with IL-8Rl or IL-8R2 migrate in response to IL-8, 
GROa and NAP-2 
Pius Loetschera’b’*, Michael Seitzb, Ian Clark-Lewis”, Marco Baggiolini”, Bernhard Mosera 
“Theodor-Kocher Institute, University of Bern, I? 0. Box, CH-3000 Bern 9, Switzerland 
bDivision of Rheumatology, University Hospital, CH-3010 Bern, Switzerland 
“Biomedical Research Centre and Department of Biochemistry, University of British Columbia, Vancouver, BC, V6T 123, Canada 
Received 11 February 1994 
AbStMCt 
Neutrophil leukocytes, the target cells for interleukin-8 and related CXC chemokines, bear high numbers of two types of IL-8 receptors (IL-8Rl 
and IL-8R2). By cDNA transfection Jurkat cell lines were generated that stably express either IL-8Rl or IL-8R2 (J-IL8Rl and J-IL8R2). J-IL8Rl 
expressed 4,000 + 1,000 copies of IL-8R1, and bound IL-8 with high affinity (Kd l-4 nM) and GROcl and NAP-2 with low affinity (Kd 200-500 nM). 
J-IL8R2 expressed 17,000 f 3,000 copies of IL-8R2, and bound all three chemokines with high affinity. Both transfectants howed a similar degree 
of chemotactic migration after stimulation with IL-8, GROa and NAP-2. All three chemokines were equally potent as attractants of J-IL8R2, whereas 
IL-8 was 300 to l,OOO-fold more potent than GROcl or NAP-2 as attractant of J-IL8Rl. The potencies, therefore, agree with the affinities of the 
ligands to IL-8Rl and IL-8R2. Our results demonstrate that both IL-8 receptors function independently, and mediate chemotaxis in response to IL-8 
and other CXC chemokines. 
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1. Introduction 
Chemokines constitute a novel family of small cytoki- 
nes which attract and activate leukocytes, and are of 
major importance as mediators of inflammation [1,2]. 
Two subfamilies are distinguished epending on the ar- 
rangement of the first two of four conserved cysteines, 
which are either separated by one amino acid (CXC 
chemokines) or adjacent (CC chemokines). IL-8 and sev- 
eral other CXC chemokines act mainly on neutrophils. 
Like other chemotactic agonists, they induce shape 
changes, chemotaxis, a transient rise of intracellular free 
Ca” ([Ca*+]J, granule exocytosis, integrin upregulation, 
formation of bioactive lipids, and the respiratory burst 
~2~31. 
Biochemical studies have shown that neutrophils ex- 
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Abbreviations: IL-8R1/2, human interleukin-8 receptor type 112; J- 
ILSRl/2, Jurkat transfectants expressing IL-8Rl/2; GROa and NAP-2 
(neutrophil-activating peptide 2) are two chemotactic ytokines related 
to IL-8; aCD3, OKT3, monoclonal antibody recognizing CD3 on T 
lymphocytes. 
press two distinct IL-8 receptors [4,5] which are now 
termed IL-8Rl and IL-8R2 [2]. IL-8 binds to both recep- 
tors with high affinity, whereas GROa, GRO/3, GROr 
and NAB-2 bind with high affinity to IL-8R2 (Kd 0.2-2.5 
nM) and low affinity to IL-8Rl (& 20&500 nM) [4-71. 
The cDNAs for IL-8Rl and IL-8R2 were cloned and 
shown to code for homologous proteins of 350 and 360 
amino acids with seven putative transmembrane do- 
mains, which are typical for G-protein coupled receptors 
[8,9]. IL-8Rl and IL-8R2 have high amino acid sequence 
identity except for the amino- and carboxyl-terminal re- 
gions (Fig. 1). The amino-terminal region, which may 
form part of the chemokine binding pocket through a 
disulfide link to the third extracellular loop [lo], is likely 
to determine ligand recognition and afI%rity [11,12], 
while the carboxyl-terminal region is thought to be im- 
portant for signalling and receptor desensitization [2]. 
Recombinant IL-8 receptors were previously expressed 
transiently in mammalian cells and shown to have simi- 
lar binding properties as their natural counterparts and 
to mediate [Ca*+]i changes [13-l 51. 
The role of IL-8Rl and IL-8R2 in the induction of 
chemotaxis and other neutrophil functions has not been 
studied. In particular, it is not clear whether the two 
receptors mediate the same cellular responses and can 
0014-5793/94/$7.00 0 1994 Federation of European Biochemical Societies. All rights reserved. 
SSDI 0014-5793(94)00194-Z 
188 
function independently of each other. In the present 
study, cDNAs coding for IL-8Rl or IL-8R2 were stably 
transfected into Jurkat cells, and the functional re- 
sponses elicited by stimulation with IL-8, GROcl and 
NAP-2 were studied. Since lymphocytes are implicated 
in inflammation, we reasoned that Jurkat cells, which are 
derived from a human T cell leukemia, would be able to 
transduce chemokine receptor signals. The present re- 
sults show that both IL-8 receptors function independ- 
ently and mediate chemotaxis in response to IL-8 and 
other CXC chemokines. 
2. Materials and methods 
2.1. Cells and transfectants 
The human T cell leukemia line, Jurkat, (a kind gift of Dr. A. Tobler, 
Central Hematology Laboratory, University Hospital, Bern) and Jur- 
kat transfectants were maintained in RPM1 1640 medium with glu- 
tamin, penicillin, streptomycin and 10% FCS. For cell culture of the 
transfectants the medium was supplemented in addition with G-418 
(GibcolBRL) at 0.8 mg/ml. 
DNA for IL-8Rl was synthetized by PCR using the primers SERll 
H3, S-CCAAGCTTACCATTGCTGAAACTGAAGAGG, and 
ASRl/Kba, S-CCTCTAGATCAGAGGTTGGAAGAGACATTG, 
and reverse transcription products from neutrophil RNA as template, 
resulting in a 1,112 bp fragment hat contained the entire coding region 
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for IL-8Rl. Following subcloning into pcDNA-1 (Invitrogen Corp.), 
nucleotide sequencing [16] revealed identity with the published se- 
quence [8]. cDNAs for human IL-8R2 were isolated as described previ- 
ously [15]. Jurkat cell lines that stably express one or the other IL-8 
receptor, J-ILIRl and J-IL8R2, were obtained as described by Moser 
et al. [ 151. Briefly, the cells were washed twice with PBS and incubated 
on ice for 5 min (5-8 x lo6 cells/800 ~1 PBS) with 20 pug linearized 
pcDNA-l/IL-8Rl or pcDNA-l/IL-8R2 (clone 202 [15]) and 10 pug lin- 
earized pSV2., vector. After electroporation (250 V, 96OpF, pulse time 
3&40 ms) with a gene pulser (Bio-Rad), the cells were placed on ice for 
10 min, diluted loo-fold with prewarmed RPM1 1640 medium contain- 
ing 10% FCS and cultured for 48 h. The medium was supplemented 
with 0.8 mg/ml G-418 (GibcolSRL), and the culture was continued 
until the control cells (no pSV2,,,, added) started to die (l&14 days). 
G-418 resistant Jurkat cell clones were obtained by limiting dilution and 
cell lines expressing IL-8Rl or IL-8R2 were identified by “‘I-IL-8 
binding. One stable clone expressing ILIRl, was isolated and termed 
J-ILIRl. Of eight clones expressing IL-8R2, the one with the highest 
‘251-IL-8 binding was selected and termed J-IL8R2. 
2.2. Binding and functional assays 
Chemokines were chemically synthesized [17], and IL-8 was labelled 
with radioactive iodine [4]. Binding studies were performed as described 
[4] using samples of 4 x lo6 J-ILIRl or J-IL8R2 cells, 2 nM ‘z51-IL-8 
and increasing concentrations of unlabeled IL-8, GROa or NAP-2. 
Changes of cytosolic free calcium concentration ([Ca2+li were deter- 
mined with cells loaded with fura- by incubation for 30 min at 37’C 
with 0.1 nmol fura2/acetoxymethylester per lo6 cells [18]. Loaded cells 
(5 x lo6 cells/ml in loading buffer) were stimulated at 37°C with a 
chemokine or aCD3 (OKT3, Ortho Diagnostic Systems), and the fluo- 
rescence-related [Ca2+li changes were recorded [18]. 
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Fig. 1. Schematic representation of the human IL-8 receptors. The 360 amino acid sequence of IL-8R2 is shown. The sequence was aligned with that 
of IL-8Rl (350 amino acids) allowing for gaps [2], and residues that differ after alignment are shown as filled circles. Diamonds designate putative 
N-linked glycosylation sites, and pinhead symbols represent lipids in the plasma membrane. Two putative disulfide bridges, formed by Cy~“~/Cys’~~ 
and Cy~~~lCy?~‘, respectively are indicated by thick lines [lo]. Note the extensive sequence similarity between IL-8Rl and IL-8R2 in most 
transmembrane domains. Highest sequence divergence is in the amino- and carboxy-terminal regions. 
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Cell migration was measured in 48-well microchemotaxis chambers 
(Neuro Probe, Inc., Cabin John, MD) [19]. Chemattractants diluted in 
HEPES-buffered RPM1 1640 sunnlemented with 1% uasteurized 
plasma protein (PPL SRK, Swiss Red Cross Laboratory, Beh, Switzer- 
land) were added to the bottom wells and 100,000 cells suspended in 
the same medium to the upper wells. A polyvinylpyrrolidone-free poly- 
carbonate membrane with 5 nm pores (Nucleopore) separating upper 
and lower wells was coated with type IV collagen [20]. After incubation 
at 37T for 3 h in humidified air with 5% CO*, the membrane was 
removed, washed on the upper side with PBS, tixed, and stained. Mi- 
grated cells were counted microscopically at 1,000 x magnification in 
five randomly selected fields per well. All assays were performed in 
triplicate. 
3. Results and discussion 
3.1. Chemokine binding to Jurkat transfectants 
Binding studies were performed with the two stably 
transfected cell lines, J-IL8Rl and J-IL8R2, which were 
found to express 4,000 f 1,000 and 17,000 + 3,000 recep- 
tors per cell, respectively. The competition for binding of 
iz51-IL-8 by unlabelled IL-8 and GROcz is shown in Fig. 
2. Both transfectants bound IL-8 with equally high affin- 
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Fig. 2. Cold ligand competition of “‘I-IL-8 binding to J-IL8Rl and 
J-IL8R2. 4 x lo6 transfected cells were incubated at 4°C with 2 nM 
iZ51-IL-8 in the presence of increasing concentrations of IL-8 (0) or 
GROa (0) and further processed as described in section 2.60-80% and 
40-5096 of IL-8Rl and IL-8R2 receptors, respectively, were occupied 
in the absence of unlabelled ligands. 
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Fig. 3. [Caz+li changes induced in J-ILIRl, J-IL8R2 and non-trans- 
fected Jurkat cells. Fluorescence changes in Fura- loaded cells (5 x lo61 
ml) were monitored during sequential stimulation (arrows) with 100 
nM IL-8 and 2 @ml ctCD3, and [Ca2Ti was calculated [18]. 
ity (& 14 nM), whereas GRO& exhibited high-affinity 
binding to J-IL8R2 (& 3 nM) and low-affiity binding 
to J-IL8Rl (Kd 300 nM). Similar results were obtained 
with NAP-2 yielding Kd values of 6 and 450 nM for 
J-IL8R2 and J-IL8R1, respectively. These results indi- 
cate that IL-8Rl and IL-8R2 can be distinguished by 
their binding of GROcz and NAP-2 but not of IL-8. 
Jurkat cells that were not transfected with IL-8Rl or 
IL-8R2 did not bind “‘1-IL-8. 
The binding properties of the transfected receptors are 
closely comparable to those of the natural IL-8 receptors 
in human neutrophils [4-6]. The present findings are in 
agreement with previous observations in transiently 
transfected E293 cells [13]. Two distinct recombinant 
IL-8 receptors were also expressed in COS cells [14]. In 
this case, however, GROcc or NAP-2 did not compete for 
1251-IL-8 binding to IL-8Rl and bound to IL-8R2 with 
markedly lower affinity than IL-8, suggesting that COS 
cells may be less convenient for the study of recombinant 
IL-8 receptors. 
3.2. Cytosolic free Cd’ changes 
A rapid and transient rise in [Ca”], is an early event 
after stimulation of leukocytes with chemotactic ag- 
onists. As shown in Fig. 3, stimulation with IL-8 induced 
a small, but significant [Ca”]i rise in J-ILSRl and J- 
IL8R2, but not in non-transfected Jurkat cells. This indi- 
cates that both transfected IL-8 receptors are functional, 
and mediate similar signal transduction events as in neu- 
trophils [3]. The maximal [Ca’+]i levels after stimulation 
with 100 nM IL-8 did not exceed 250 nM. A higher and 
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Fig. 4. [Ca2+li changes induced in J-ILSRl and J-IL8R2 cells by IL-8 
and GROa. Fura- loaded cells (5 x lO’?ml) were stimulated with 100, 
10, and 1 nM IL-8 or GROa (a-c) and the [Ca2+li changes determined 
[18]. The recordings are representative for three independent experi- 
ments. 
more protracted rise was obtained after addition of 
oCD3. The [Ca”]i rise induced by IL-S was concentra- 
tion dependent in both J-IL8Rl and J-IL8R2 (Fig. 4). 
Stimulation with up to 100 nM GROa (Fig. 4) or NAP-2 
(not shown) induced virtually identical, concentration- 
dependent [Ca”], changes in J-IL8R2, but no [Ca”]i rise 
in J-IL8Rl. The [Ca”]i response in J-IL8Rl was consis- 
tently weaker than in J-IL8R2. Since both tranfectants 
bound IL-8 with high affinity, these differences may have 
resulted from the approximately 4-fold difference in the 
density of the expressed receptors. 
As expected on the basis of the receptor binding data, 
mutual cross-desensitization of the Ca2’ response was 
obtained with IL-8 and GROa in J-IL8R2 but not in 
J-IL8Rl (not shown). These observations are in agree- 
ment with our former data in neutrophils (which bear 
both types of IL-8 receptors) where stimulation with IL-8 
abrogated the response to GROol whereas GROa only 
partially prevented the response to IL-8 [4]. Addition of 
EGTA to the assay buffer to chelate extracellular Ca*’ 
did not prevent the rise in [Ca”],, but reduced the rate 
of increase by about 30% indicating that Ca*’ release 
from intracellular stores and Ca2’ influx through the 
plasma membrane occurred upon stimulation. 
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3.3. Chemotaxis 
Chemotaxis is considered the most important func- 
tional response to CXC chemokines. Using the trans- 
fected cells, we, therefore, compared the capacity of each 
of the two IL-8 receptors to mediate this response. As 
shown in Fig. 5, IL-8-dependent migration was observed 
with both J-IL8Rl and J-IL8R2. The effect was concen- 
tration dependent and bimodal, which is characteristic 
for leukocyte chemotaxis in vitro. In some experiments, 
as shown in Fig. 5, no bimodal curve was obtained for 
J-IL8Rl chemotaxis in response to GROcl or NAP-2 up 
to 1 PM. With both transfected cells, maximum migra- 
tion in 3 h amounted to 175 f 46 (+ SD.) cells per five 
high-power fields (mean of four separate experiments), 
and was obtained at IL-8 concentrations of 1 nM, which 
corresponds closely to the optimum chemotactic oncen- 
tration for human neutrophils. GROcl and NAP-2 were 
chemotactic for either type of transfected cells, but the 
concentrations yielding maximum effects differed by up 
to a thousand-fold, namely l-10 nM for J-IL8R2 and 
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Fig. 5. In vitro chemotaxis of J-ILIRl, J-IL8R2 and non-transfected 
Jurkat cells. Concentration-dependent effects of IL-8 (0) and GROa 
(0) on cell migration were determined as described in section 2. Results 
are expressed as the mean number (+ S.D.) of migrating cells per five 
high-power fields of triplicate assays. Number of cells migrated in the 
absence of added chemokines (random migration) were 22 + 4 and 
8 zb 5 for transfected and normal Jurkat cells, respectively. Data shown 
are representative for four independent experiments. 
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0.3-l ,uM for J-IL8Rl (Fig. 5). Non-transfected Jurkat 
cells did not respond to IL-S, GROol or NAP-2. 
Since GROa and NAP-2 at concentrations up to 100 
nM did not induce [Ca*+]i changes in J-IL8R1, it was 
somewhat surprising to observe a full chemotactic re- 
sponse. It is known, however, that shape changes in 
neutrophils are not affected by depletion of mobilizable 
storage pool Ca*’ [2 1,221, and that neutrophil migration 
on certain surfaces is not related to [Ca”‘]i changes [23]. 
While considerable information is available on gran- 
ulocyte chemotaxis and migration, little is known about 
the mechanism of migration of lymphocytes. Several che- 
moattractant receptors have been characterized in my- 
eloid cells, and all shown to belong to the superfamily of 
seven-transmembrane-domain receptors [2]. Seven- 
transmembrane-domain receptors have also been identi- 
fied in lymphocytes through cDNA cloning. EBIl [24], 
BRLl [25] and MDRlS (Barella et al., in preparation) 
are strongly expressed in normal and leukemic human B 
cells, and share 3&40% sequence identity with the IL-8 
receptors. Another receptor, 6H1, was shown to be ex- 
pressed primarily in activated chicken T lymphocytes 
[26]. High expression in both myeloid and lymphoid 
cells, including Jurkat cells, was reported for a human 
receptor termed pBE1.3 [271 or LESTR52 [28], which 
was isolated from human monocyte cDNA libraries. The 
ligands for these receptors are still unknown. Because of 
their relatedness to the IL-8 receptors, they may mediate 
lymphocyte migration, although, at least for MDR15 
and LESTR52, none of the known chemoattractants 
were shown to bind ([28] and Barella et al., in prepara- 
tion). 
Several papers have reported that IL-8 is chemotactic 
for human T lymphocytes [l]. The effects, however, are 
much less pronounced than those observed for neutro- 
phils [2]. We were unable to detect [Ca*‘]i changes [29] 
or significant migration responses by human blood lym- 
phocytes challenged with IL-8 (T. Geiser, unpublished 
results). Our present data show that leukemic T cells are 
able to migrate, but only respond to CXC chemokines 
when transfected with cDNAs for one of the IL-8 recep- 
tors. In an earlier study, we showed that lymphocytes 
and particularly Jurkat cells express low levels of IL-8Rl 
mRNA (that could be demonstrated only by reverse 
transcriptase-PCR) while mRNA for IL-8R2 was not 
detected [15]. The lack of demonstrable specific binding 
of IL-8 is in agreement with these observations indicating 
that the level of IL-8 receptors on lymphocytes is ex- 
tremely low. Lymphocytes have been shown to respond 
to CC chemokines, including RANTES, MIP-la, MIP- 
l/J [30-331 and the CXC chemokine IPlO [33], which is 
inactive on neutrophils [34]. 
Two main conclusions can be drawn from our study. 
(i) Both IL-8 receptors, IL-8Rl and IL-8R2, which are 
expressed on human neutrophils mediate chemotaxis in 
response to IL-8 and related CXC chemokines. They are 
equally responsive to IL-8, and can function independ- 
ently of each other. (ii) T lymphocytic cells are able to 
migrate in response to CXC chemokines when they ex- 
press the appropriate receptors. Cells that express IL- 
8R2 can be stimulated equally well with IL-8, GROa and 
NAP-2, and are thus likely to be responsive to all CXC 
chemokines known to be active on neutrophils. Despite 
their low binding affinity, GROa and NAP-2 are able to 
attract cells that exclusively bear IL-8Rl receptors when 
supplied at concentrations close to their Kd values. 
Acknowledgments: We are grateful to Regula Stuber for outstanding 
technical assistance and to Dr. Beatrice Dewald for critically reading 
the manuscript. This work was supported by Grant 31-25700.88 from 
the Swiss National Science Foundation and the Protein Engineering 
Network of Centres of Excellence (PENCE), Canada. 
References 
[l] Oppenheim, J.J., Zachariae, C.O.C., Mukaida, N. and Mat- 
sushima, K. (1991) Annu. Rev. Immunol. 9, 61748. 
[2] Baggiolini, M., Dewald, B. and Moser, B. (1994) Adv. Immunol. 
55, 97-179. 
[3] Baggiolini, M., Imboden, P. and Detmers, P. (1992) in: Cytokines. 
Vol. 4. Interleukin-8 (NAP-l) and related chemotactic ytokines 
(Baggiolini, M. and Sorg, C. Eds.) Karger, Basel, pp. 1-17. 
[4] Moser, B., Schumacher, C., von Tscharner, V., Clark-Lewis, I. and 
Baggiolini, M. (1991) J. Biol. Chem. 266, 1066610671. 
[5] Schumacher, C., Clark-Lewis, I., Baggiolini, M. and Moser, B. 
(1992) Proc. Natl. Acad. Sci. USA 89, 10542-10546. 
[6] Schnitzel, W., Garbeis, B., Monschein, U. and Besemer, J. (1991) 
Biochem. Biophys. Res. Commun. 180, 301-307. 
[7j Geiser, T., Dewald, B., Ehrengruber, M.U., Clark-Lewis, I. and 
Baggiolini, M. (1993) J. Biol. Chem. 268, 15419-15424. 
[8] Holmes, W.E., Lee, J., Kuang, W.-J., Rice, G.C. and Wood, WI. 
(1991) Science 253, 1278-1280. 
[9] Murphy, P.M. and Tiffany, H.L. (1991) Science 253, 1280-1283. 
[lo] Hebert, C.A., Chuntharapai, A., Smith, M., Colby, T., Kim, J. and 
Horuk, R. (1993) J. Biol. Chem. 268, 18549-18553. 
[l l] LaRosa, G.J., Thomas, K.M., Kaufmann, M.E., Mark, R., White, 
M., Taylor, L., Gray, G., Witt, D. and Navarro, J. (1992) J. Biol. 
Chem. 267, 25402-25406. 
[12] Gayle III, R.B., Sleath, P.R., Srinivason, S., Birks, C.W., Weera- 
wama, K.S., Cerretti, D.P., Kozlosky, C.J., Nelson, N., Vanden 
Bos, T. and Beckmann, M.P. (1993) J. Biol. Chem. 268,7283-7289. 
[13] Lee, J., Horuk, R., Rice, G.C., Bennett, G.L., Camerato, T. and 
Wood, W.I. (1992) J. Biol. Chem. 267, 16283-16287. 
[14] Cerretti, D.P., Kozlosky, C.J., Vanden Bos, T., Nelson, N., 
Gearing, D.P. and Beckmann, M.P. (1993) Mol. Immunol. 30, 
359-367. 
[15] Moser, B., Barella, L., Mattei, S., Schumacher, C., Boulay, F., 
Colombo, M.P. and Baggiolini, M. (1993) Biochem. J. 294, 285- 
292. 
[16] Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc. Natl. Acad. 
Sci. USA 74, 5463-5467. 
[17] Clark-Lewis, I., Moser, B., Walz, A., Baggiolini, M., Scott, G.J. 
and Aebersold, R. (1991) Biochemistry 30, 3128-3135. 
[18] von Tschamer, V., Prod’hom, B., Baggiolini, M. and Reuter, H. 
(1986) Nature 324, 369-372. 
[19] Falk, W., Goodwin Jr., R.H. and Leonard, E.J. (1980) J. Immu- 
nol. Methods 33, 239-247. 
[20] Pilaro, A.M., Sayers, T.J., McCormick, K.L., Reynolds, C.W. and 
Wiltrout, R.H. (1990) J. Immunol. Methods 135, 213-224. 
192 P Loetscher et al.IFEBS Letters 341 (1994) 187-192 
[21] Baggiolini, M. and Kernen, P. (1992) News Physiol. Sci. 7, 215- 
219. 
[22] Jaconi, M.E.E., Theler, J.M., Schlegel, W., Appel, R.D., Wright, 
S.D. and Lew, P.D. (1991) J. Cell Biol. 112, 1249-1257. 
[23] Hendey, B., Klee, C.B. and Maxtield, F.R. (1992) Science 258, 
296-299. 
[24] Birkenbach, M., Josefsen, K., Yalamanchili, R., Lenoir, G. and 
Kieff, E. (1993) J. Viol. 67, 22092220. 
[25] Dobner, T., Wolf, I., Emrich, T. and Lipp, M. (1992) Eur. J. 
Immunol. 22,2795-2799. 
[26] Kaplan, M.H., Smith, D.I. and Sundick, R.S. (1993) J. Immunol. 
151, 628-636. 
[271 Federsppiel, B., Melhado, I.G., Duncan, A.M.V., Delaney, A., 
Schappert, K., Clark-Lewis, I. and Jiik, F.R. (1993) Genomics 16, 
707-712. 
[28] Loetscher, M., Geiser, T., G’Reilly, T., Zwahlen, R., Baggiolini, 
M. and Moser, B. (1994) J. Biol. Chem. 269, 232-237. 
[29] Thelen, M., Peveri, P, Kernen, P., von Tscharner, V., Walz, A. 
and Baggiolmi, M. (1988) FASEB. J. 2,2702-2706. 
[30] Schall, T.J., Bacon, K., Toy, K.J. and Goeddel, D.V. (1990) Na- 
ture 347,669-671. 
[31] Tanaka, Y., Adams, D.H., Hubscher, S., Hirano, H., Siebenlist, 
U. and Shaw, S. (1993) Nature 361, 79-82. 
[32] Taub, D.D., Conlon, K., Lloyd, A.R., Oppenheim, J.J. and Kel- 
vin, D.J. (1993) Science 260, 355-358. 
[33] Taub, D.D., Lloyd, A.R., Conlon, K., Wang, J.M., Ortaldo, J.R., 
Harada, A., Matsushima, K., Kelvin, D.J. and Oppenheim, J.J. 
(1993) J. Exp. Med. 177, 1809-1814. 
[34] Dewald, B., Moser, B., Barella, L., Schumacher, C., Baggiolini, M. 
and Clark-Lewis, I. (1992) Immunol. Lett. 32, 81-84. 
